Clinuvel Pharmaceuticals (CUV) investor relations material

Executive summary

• Revenue grew 4% year-over-year to a record $36.93 million for the half year ended 31 December 2025, marking the twentieth consecutive profitable period.

• Net profit after tax was $10.4 million, down 26% year-over-year, reflecting increased investment in R&D and business expansion.

• Cash reserves rose 4% to $233 million, supporting ongoing operations, self-funded growth, and future initiatives.

• Maintained a debt-free balance sheet for 21 years, with no equity dilution since 2016.

• EMA approved year-round SCENESSE® treatment for EPP, and an application for ADR Level II uplisting to Nasdaq was filed.

Financial highlights

• Total revenue, including commercial, special access schemes, and interest income, reached $40.6 million, with a $4.7 million unrealized FX loss impacting reported income.

• Expenses increased 22% to $26.0 million, mainly due to higher personnel, R&D, clinical, and commercial distribution costs.

• Interest income rose 14% to $5.3 million, driven by higher cash balances and favorable deposit rates.

• Basic earnings per share declined 26% to $0.21.

• Dividend of 5.0 cents per share fully franked was paid in September 2025.

Outlook and guidance

• Sufficient funds to run programs through 2028, with continued investment in R&D, manufacturing, and expansion of SCENESSE® distribution.

• Key catalysts include topline results for CUV105 (H2 2026), start of CUV107, preclinical readout for new peptide formulation (H1 2026), and Nasdaq ADR uplisting.

• Anticipates higher second-half revenues due to seasonal demand in EU and U.S.

• Full financial year results to be reported in August 2026.